NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors

NCT03522142
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed
https://ClinicalTrials.gov/show/NCT03522142

Comments are closed.

Up ↑